MedTrace Logo

Metformin for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD)

NCT00736385 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2024-01-26

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to find out if Metformin is safe and useful in the treatment of NAFLD.

Conditions

Interventions

DRUG

Glucophage (Metformin)

metformin XR 2000 mg daily for 12 months

DRUG

Placebo

placebo 2000 mg daily for 12 months

Sponsors & Collaborators

Principal Investigators

  • Manal F Abdelmalek, MD, MPH · Duke University Medical Center, Department of Medicine, Division of Gastroenterology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2012-12-31
Completion
2012-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00736385 on ClinicalTrials.gov